We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
Read MoreHide Full Article
All the large drugmakers in the drug/biotech sector have already reported their fourth-quarter results. Overall, it has been a mixed earnings season for them, with most companies beating estimates for earnings but missing the same for sales. Most large drugmakers issued a conservative guidance for 2023.
The earnings season for the drug/biotech sector is now in its final stretch, with some smaller companies due to report their fourth-quarter results.
Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.
As of Feb 15, per the Earnings Trends report, 75.0% of the Medical sector participants, constituting 92.7% of the sector’s market capitalization, have already reported earnings. While 76.2% of the companies beat on earnings, 73.8% surpassed on revenues. Earnings decreased 6.5% year over year, while revenues rose 4.8%.
Overall, fourth-quarter earnings of the Medical sector are expected to decline 1.2%, while sales are projected to increase 3%.
Here we discuss four companies, Moderna (MRNA - Free Report) , Bausch Health Companies (BHC - Free Report) , Alnylam Pharmaceuticals (ALNY - Free Report) and Agios Pharmaceuticals (AGIO - Free Report) , which are set to report fourth-quarter results on Feb 23.
Moderna
This large biotech’s surprise history has been mixed, with earnings beating estimates in three of the trailing four quarters while missing the same once. The average surprise is 20.04%. In the last reported quarter, the company delivered a negative earnings surprise of 16.78%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Moderna has an Earnings ESP of -6.55% and a Zacks Rank #4 (Sell). The Zacks Consensus Estimate for earnings stands at $4.66 per share.
We expect sales of Moderna’s mRNA-based COVID vaccine to be significantly lower than the prior-quarter levels, with the impact of the pandemic receding. Apart from its COVID-19 vaccine, Moderna is developing more than 30 candidates in different stages of clinical studies, majorly mRNA-based products targeting different indications, including cancer.
Bausch Health Companies
This pharmaceutical company has a rather poor track record, having missed earnings in three of the past four quarters while beating in one. In the last reported quarter, it missed earnings expectations by 17.39%. It missed earnings estimates by 17.03%, on average, in the last four quarters.
Bausch Health has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings stands at 92 cents share.
Alnylam Pharmaceuticals
Alnylam’s surprise history has been poor, with earnings missing estimates in all the trailing four quarters. The average negative surprise is 42.61%. In the last reported quarter, the company’s earnings missed estimates by 78.49%.
Alnylam Pharmaceuticals, Inc. Price and EPS Surprise
Alnylam has an Earnings ESP of +3.00% and a Zacks Rank #3, which suggests an earnings beat. The Zacks Consensus Estimate stands at a loss of $2.13 per share.
Agios Pharmaceuticals
Agios’ surprise history has been mixed, with earnings beating estimates in three of the trailing four quarters while missing the same once. The four-quarter average surprise is 5.15%. In the last reported quarter, the company delivered an earnings surprise of 14.86%.
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Image: Bigstock
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
All the large drugmakers in the drug/biotech sector have already reported their fourth-quarter results. Overall, it has been a mixed earnings season for them, with most companies beating estimates for earnings but missing the same for sales. Most large drugmakers issued a conservative guidance for 2023.
The earnings season for the drug/biotech sector is now in its final stretch, with some smaller companies due to report their fourth-quarter results.
Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.
As of Feb 15, per the Earnings Trends report, 75.0% of the Medical sector participants, constituting 92.7% of the sector’s market capitalization, have already reported earnings. While 76.2% of the companies beat on earnings, 73.8% surpassed on revenues. Earnings decreased 6.5% year over year, while revenues rose 4.8%.
Overall, fourth-quarter earnings of the Medical sector are expected to decline 1.2%, while sales are projected to increase 3%.
Here we discuss four companies, Moderna (MRNA - Free Report) , Bausch Health Companies (BHC - Free Report) , Alnylam Pharmaceuticals (ALNY - Free Report) and Agios Pharmaceuticals (AGIO - Free Report) , which are set to report fourth-quarter results on Feb 23.
Moderna
This large biotech’s surprise history has been mixed, with earnings beating estimates in three of the trailing four quarters while missing the same once. The average surprise is 20.04%. In the last reported quarter, the company delivered a negative earnings surprise of 16.78%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Moderna has an Earnings ESP of -6.55% and a Zacks Rank #4 (Sell). The Zacks Consensus Estimate for earnings stands at $4.66 per share.
We expect sales of Moderna’s mRNA-based COVID vaccine to be significantly lower than the prior-quarter levels, with the impact of the pandemic receding. Apart from its COVID-19 vaccine, Moderna is developing more than 30 candidates in different stages of clinical studies, majorly mRNA-based products targeting different indications, including cancer.
Bausch Health Companies
This pharmaceutical company has a rather poor track record, having missed earnings in three of the past four quarters while beating in one. In the last reported quarter, it missed earnings expectations by 17.39%. It missed earnings estimates by 17.03%, on average, in the last four quarters.
Bausch Health Cos Inc. Price and EPS Surprise
Bausch Health Cos Inc. price-eps-surprise | Bausch Health Cos Inc. Quote
Bausch Health has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings stands at 92 cents share.
Alnylam Pharmaceuticals
Alnylam’s surprise history has been poor, with earnings missing estimates in all the trailing four quarters. The average negative surprise is 42.61%. In the last reported quarter, the company’s earnings missed estimates by 78.49%.
Alnylam Pharmaceuticals, Inc. Price and EPS Surprise
Alnylam Pharmaceuticals, Inc. price-eps-surprise | Alnylam Pharmaceuticals, Inc. Quote
Alnylam has an Earnings ESP of +3.00% and a Zacks Rank #3, which suggests an earnings beat. The Zacks Consensus Estimate stands at a loss of $2.13 per share.
Agios Pharmaceuticals
Agios’ surprise history has been mixed, with earnings beating estimates in three of the trailing four quarters while missing the same once. The four-quarter average surprise is 5.15%. In the last reported quarter, the company delivered an earnings surprise of 14.86%.
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. price-eps-surprise | Agios Pharmaceuticals, Inc. Quote
Agios has an Earnings ESP of -2.02% and holds a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for loss stands at $1.59 per share.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.